FDA accepts New Drug Application for the treatment of MoCD Type A
Molybdenum cofactor deficiency (MoCD): ultra-rare and destructive, so urgent diagnosis is crucial
Be ready to take
action immediately
The impact of MoCD on newborns and their families can be profound and prolonged. Identifying MoCD Type A early can be the first step in making a difference in the lives of these newborns and their families.
MoCD is a rare neurological disorder in newborns that can lead to severe brain toxicity, developmental delays, and death.1 Symptoms such as intractable seizures often appear within hours to days following birth.1-3 Progression is rapid, so clinicians need to take action as soon as symptoms occur.4,5
Origin believes that an ultra-rare disorder like MoCD deserves focus and commitment just like more common life-threatening diseases. We are using our unique expertise and specialized resources to alert clinicians about MoCD Type A and give them the tools to diagnose it as early as possible. Dedicated to bringing timely therapy to children born with MoCD Type A, we are developing a novel substrate replacement therapy that is currently being studied in clinical trials.
- Mechler K et al. Genet Med. 2015;17(12):965-970.
- Veldman A et al. Pediatrics. 2010;125(5):e1249-e1254.
- Schwahn BC et al. Lancet. 2015;386(10007):1955-1963.
- Durmaz MS et al. Radiol Case Rep. 2018;13(3):592-595.
- Zaki MS et al. Eur J Paediatr Neurol. 2016;20(5):714-722.
